Skip to main content
. 2023 Aug 16;13:1223282. doi: 10.3389/fonc.2023.1223282

Figure 2.

Figure 2

Forest Plot of OS for Lenvatinib + Pembrolizumab Versus Sunitinib Treatment. CI, confidence interval; HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; ITT, intention to treat; L+P, lenvatinib + pembrolizumab; MSKCC, Memorial Sloan Kettering Cancer Center; NE, not estimable; OS, overall survival; S, sunitinib.